CD8A and neoplasm: Interestingly, ADAMTS-derived cleavage fragments of versican (e.g., versikine [209]) have been shown to modulate key aspects of the tumour immune landscape, including modulation of DCs and CD8+ T-cell recruitment in myeloma, lung cancer, and CRC (Figure 3D) [210,211,212,213].